Twenty cases of sympathetic ophthalmia

TOM JENNINGS AND HOWARD H TESSLER

From the Department of Ophthalmology, University of Illinois Eye and Ear Infirmary, College of Medicine at Chicago, 1855 W Taylor Street, Chicago, IL 60612, USA

SUMMARY We reviewed the charts of 20 patients with sympathetic ophthalmia who were seen in the uveitis clinic at the Eye and Ear Infirmary within an 11-year period. Of these 20 patients 14 maintained 20/50 or better visual acuity in at least one eye. We found early enucleation to be associated with a better visual prognosis, possibly due to earlier diagnosis and faster, more aggressive therapy rather than a reduction in antigenic load. The clinical appearance of Dalen-Fuchs nodules appears to indicate a more severe stage of disease. Chlorambucil was useful in patients with severe disease. To be effective and to lessen its side effects chlorambucil was given in daily dosages that were increased weekly over a short period to achieve bone marrow suppression. After a course of chlorambucil therapy intraocular inflammation could be controlled with topical steroids alone.

Sympathetic ophthalmia is a rare bilateral uveitis that can occur within a variable period of time after a penetrating injury or manipulation of the eye. We review 20 cases of sympathetic ophthalmia and contrast our clinical experience with that reported in the literature. We were specifically interested in finding out whether there were diagnostic clues for severity and whether we could elicit a better treatment regimen from previous results.

Methods and materials

We reviewed the charts of patients with sympathetic ophthalmia seen in the uveitis clinic at the Illinois Eye and Ear Infirmary from 1974 to 1985. Each patient's subsequent progress was determined, whenever possible, by telephoning the referring physician. Nine patients were followed up to the present time, three patients were followed up to their death, and three patients were seen for one, three, and five years. Five patients were seen for the referral visit only. Visual acuity, onset of injury and of sympathetic ophthalmia, time of enucleation if performed, and treatment regimen were recorded. The severity of the sympathetic ophthalmia was rated as follows: the inflammation was defined as mild if it could be controlled with topical steroids or moderate if it could be managed with systemic steroids. The inflammation was considered severe if it could not be controlled with systemic steroids or if the corticosteroids could not be tapered without exacerbating the inflammation.

Fundus lesions thought to be clinically compatible with the histopathological Dalen-Fuchs nodule (granuloma) were noted. These white lesions were termed Dalen-Fuchs nodules if they were 1/10 disc diameter or less in size. The lesions had discrete hard edges and often looked like 'pin pricks' at the level of the retinal pigment epithelium (RPE). They resembled tiny hard drusen. When active, the Dalen-Fuchs nodules appear to have substance and when inactive appear as depigmented tiny spots.

For patients who had had several operations the period between the last operation and the onset of sympathetic ophthalmia was considered to be the interval between the inciting injury and the onset of symptoms. Patient 16 was excluded from the analysis of intervals because the date of onset of sympathetic ophthalmia was not known.

Chlorambucil was given to patients with severe disease after they were informed of its potential side
Twenty cases of sympathetic ophthalmia

effects. The initial dosage was 2 mg/day orally, which was increased by 2 mg/day each week. Prednisone dosage was concurrently reduced to zero with therapeutic response or stabilisation. Platelet and white blood cell counts were monitored weekly. When the platelet count was below 100×10^9/l and/or the white blood cell count was below 2-8×10^9/l, chlorambucil therapy was discontinued.

Results

The 20 cases included in our study are shown in Table 1. They represented about 1.4% of the total number of referred uveitis patients seen at the Eye and Ear Infirmary. Five patients had mild disease, nine had moderate disease, and six had severe disease. Symptoms developed in seven patients within 12 weeks of the injury, in four within three to six months of the injury, and in eight more than six months after injury. Although patient 15 showed symptoms several days after the injury, this time interval could not be defined more precisely. The shortest documented time interval was four weeks and the longest 56 years. Eleven patients had additional procedures besides the original repair in the exciting eye before the onset of sympathetic ophthalmia (Table 1).

Fourteen of 20 patients maintained 20/50 or better visual acuity in at least one eye (Table 1). There was no great difference in the visual prognosis whether the patient had mild, moderate, or severe disease. Four of five patients with mild disease, six of nine patients with moderate disease, and four of six patients with severe disease maintained a visual acuity of 20/50 or better.

Nine patients underwent enucleation of the exciting eye. In five patients enucleation was performed within two weeks of the onset of symptoms (range, 4 to 11 days; mean, 6-6 days; Table 2). Four of these patients with early enucleations had final visual acuities ranging from 20/20 to 20/40, and the fifth (no. 5) had a severe cataract and 20/100 visual acuity. Three of these five patients who underwent early enucleation had severe disease.

The three patients whose eyes were enucleated after two weeks from the onset of symptoms (range, 5 to 20 weeks; mean, 13-7 weeks) had visual acuities of 20/50, counting fingers, and hand motion. Two of these patients had moderate disease, and one had mild disease. An additional patient (no. 17) underwent enucleation before the onset of symptoms and had 20/20 visual acuity.

Dalen-Fuchs nodules were seen in one of the six patients with mild disease, in two of nine patients with moderate disease, and in all six patients with severe disease.

We give an illustrative case report of severe sympathetic ophthalmia that was treated with chlorambucil.

CASE REPORT

On 27 August 1978 a 6-year-old white girl sustained a penetrating corneal laceration with protruding lens and vitreous. The wound was repaired within five hours of the injury. Following the injury the visual acuity in the right eye was hand motion. On 23 September the anterior chamber in the right eye was flat and the retina was totally detached. In the left eye an iritis with keratic precipitates, 4+ flare with fibrinous strands and 3-4+ cells with 340° of posterior synechiae were present. The left fundus was normal except for a hyperaemic disc. Because the retinal detachment was believed to be unreparable, the right eye was enucleated on 27 September 1978. Histopathological examination showed sympathetic ophthalmia.

The patient was put on a regimen of oral prednisone, 60 mg/day, for several weeks. The fibrin in her anterior chamber disappeared, but 3+ flare and 3+ cells remained. On 12 October 1978 her visual acuity decreased to 20/40, and she was cushingoid. The prednisone was tapered to 80 mg every other day. On 2 November pigment clumping in the macula and several Dalen-Fuchs nodules were seen in the peripheral retina. Since the fundal lesions developed in spite of the high-dose therapy, she was initially given 2 mg of chlorambucil daily (Fig. 1), as described. By late December her white blood cell and platelet counts decreased to 3-5 and 90×10^9/l respectively, and the anterior chamber inflammation subsided. At this time she was taking 10 mg of chlorambucil daily. By 4 January 1979 chlorambucil and the remaining small dose of prednisone were discontinued. The total dose of chlorambucil was 518 mg. For the next month topical steroids were used to control her inflammation and then were also discontinued. She has had no recurrence of the inflammation after seven years, and her visual acuity is 20/25.

The concurrent improvement in ocular inflammation and depression of white blood cell count occurred in patients 17, 19, and 20 also.

Discussion

According to Duke-Elder 80% of sympathetic ophthalmia cases occur within three months of the injury.¹ In our small series the incidence was 40% during that time period, possibly because we see only referred patients in our clinic. Such cases tend to be more complicated and may represent more atypical cases of sympathetic ophthalmia.

An interesting finding in our review is that the clinical presence of Dalen-Fuchs nodules appeared to
### Table 1  Clinical data of patients with sympathetic ophthamia

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age at injury (yr), race, sex</th>
<th>Injury</th>
<th>Signs and symptoms of sympathetic ophthamia (interval from last surgery to inflammation)</th>
<th>Enucleation Therapy</th>
<th>Visual acuity</th>
<th>Sympathetic ophthamia interval from onset to last observation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mild cases</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>71 Oriental man</td>
<td>9/77 extracapsular cataract extraction OD with vitreous loss, intraocular steroid injection, 2 vitrectomies</td>
<td>16/3/79 3-week history of diminished visual acuity (2 yrs 7 mo)</td>
<td>29/3/79 OD Topical steroids</td>
<td>E</td>
<td>20/50 4 yr</td>
</tr>
<tr>
<td>2</td>
<td>60 white man</td>
<td>5/78 extracapsular cataract extraction OS, severe phacoanaphylaxis, lens nucleus into posterior chamber; 6/78 vitreoscleral OS</td>
<td>9/78 anterior chamber inflammation; Dalen-Fuchs nodules (3 mo)</td>
<td>—</td>
<td>Topical steroids x6 mo</td>
<td>20/30 20/40 6 mo</td>
</tr>
<tr>
<td>3</td>
<td>26 white man</td>
<td>7/78 OD corneoscleral laceration</td>
<td>9/78 anterior chamber inflammation (2 mo)</td>
<td>—</td>
<td>Topical steroids</td>
<td>LP 20/50 1 mo</td>
</tr>
<tr>
<td>4</td>
<td>17 black man</td>
<td>6/78 OD corneal laceration; sector iridectomy several days later; 8/78 choroidal effusions drained; 4/80 penetrating keratoplasty OD</td>
<td>6/80 anterior chamber inflammation; depigmented areas in retina (2 mo)</td>
<td>—</td>
<td>Topical steroids</td>
<td>HM 20/20 5 yr</td>
</tr>
<tr>
<td>5</td>
<td>58 white man</td>
<td>9/12/81 globe perforation with retrolubar injection OD; 11/12/81 perforation sutured; 18/12/81 vitrectomy</td>
<td>24/1/83 anterior chamber inflammation (13 mo)</td>
<td>28/1/83 OS Topical steroids</td>
<td>E</td>
<td>20/100 (cataract)</td>
</tr>
<tr>
<td><strong>Moderate cases</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>12 Hispanic man, boy</td>
<td>foreign body injury OD</td>
<td>2/74 2-month history of pain, blurriness (56 yr)</td>
<td>10/5/74 OD Topical/systemic steroids</td>
<td>E</td>
<td>CF 1.5m 3 mo</td>
</tr>
<tr>
<td>7</td>
<td>38 Hispanic man, boy</td>
<td>1948 struck in OD; 10/74 traumatic cataract removed</td>
<td>20/12/74 anterior chamber inflammation; 2-day history decreased visual acuity OD (2 mo)</td>
<td>26/12/74 OD Topical/systemic steroids</td>
<td>E</td>
<td>20/20 1 yr</td>
</tr>
<tr>
<td>8</td>
<td>50 white man, boy</td>
<td>1960 cataract extraction OD, 3 days later, extraction OD; third day after surgery, trauma OS</td>
<td>3/4 weeks later anterior chamber inflammation (3-4 wk)</td>
<td>—</td>
<td>Topical/systemic steroids</td>
<td>20/300 LP 13 yr</td>
</tr>
<tr>
<td>9</td>
<td>9 black boy, boy</td>
<td>traumatic cataract OS; 6 months later; cataract extraction</td>
<td>11/82 anterior chamber inflammation; Dalen-Fuchs nodules (20 yr)</td>
<td>—</td>
<td>Topical/systemic steroids</td>
<td>20/20 NLP 3 yr</td>
</tr>
<tr>
<td>10</td>
<td>72 black man, boy</td>
<td>no history of trauma; 1972 OD cataract; 1974 unrepairable retinal detachment OS</td>
<td>2/79 decreased visual acuity OD (7 yr)</td>
<td>6/79 OS</td>
<td>Topical/systemic steroids</td>
<td>HM E 2 yr</td>
</tr>
<tr>
<td>11</td>
<td>28 black man, boy</td>
<td>10/79 penetrating injury OS; repair delayed 2 weeks</td>
<td>12/79 anterior chamber and posterior inflammation (2 mo)</td>
<td>—</td>
<td>Topical/systemic steroid</td>
<td>20/25 20/40 *</td>
</tr>
<tr>
<td>12</td>
<td>9 white boy, boy</td>
<td>1982 bottle rocket injury OD (no perforation noted, but eye not explored)</td>
<td>11/85 anterior chamber inflammation; Dalen-Fuchs nodules (3 yr)</td>
<td>—</td>
<td>Topical/systemic steroids</td>
<td>20/200 20/20 *</td>
</tr>
<tr>
<td>13</td>
<td>9 Hispanic girl, girl</td>
<td>5/84 stuck OS; total hyphaema washed out; 10 days later, wound dehiscence</td>
<td>6/84 anterior chamber inflammation (1 mo)</td>
<td>—</td>
<td>Topical/systemic steroids</td>
<td>HM 20/20 1 yr</td>
</tr>
<tr>
<td>14</td>
<td>6 white boy, boy</td>
<td>24/4/85 corneal laceration OS; flat anterior chamber</td>
<td>2/7/85 anterior chamber inflammation; Dalen-Fuchs nodules (3 mo)</td>
<td>—</td>
<td>Topical/systemic steroids</td>
<td>20/25 20/40 10 mo</td>
</tr>
<tr>
<td><strong>Severe cases</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>10 white boy, boy</td>
<td>23/2/75 bullet wound OS</td>
<td>Several days later, anterior chamber inflammation; Dalen-Fuchs nodules (less than 14 days)</td>
<td>1/3/75 OS</td>
<td>Topical/systemic steroids; cyclophosphamide; chlorambucil</td>
<td>20/40 E 5 yr</td>
</tr>
</tbody>
</table>
correlate with the severity of the disease. (See ‘Materials and methods’ for clinical definition of Dalen-Fuchs nodule). In our series one patient with mild disease, a few patients with moderate disease, and all the patients with severe disease had Dalen-Fuchs nodules. Histological studies support this concept. Dalen-Fuchs nodules stained with monoclonal antibody to specific lymphocyte receptors show histiocytes and suppressor/cytotoxic T cells. Jakobiec and coworkers suggest that these T cells might be activated cytotoxic effector T cells. Some cells in the Dalen-Fuchs nodules are thought to be transformed retinal pigment epithelial cells. If it is shown that Dalen-Fuchs nodules represent areas of autoimmune activity, it is not surprising that their appearance correlates with severity of disease.

Enucleation within two weeks of the onset of sympathetic ophthalmia has been associated with a better visual outcome and has been advocated by some investigators. Others believe that enucleation of an exciting eye after the onset of sympathetic ophthalmia has no effect. Our data support the finding that early enucleation results in a better visual prognosis. However, patients who underwent early enucleation generally had more severe clinical disease by our criteria. Early enucleation may be associated with earlier diagnosis and quicker, more aggressive treatment. We recommend that a patient with sympathetic ophthalmia who has an exciting eye with no or bare light perception should undergo enucleation, since it may offer some therapeutic benefit. Moreover, histopathological examination can confirm a clinical diagnosis. We do not advocate enucleating eyes with useful vision.

As illustrated in our case report, we have found chlorambucil dramatically to reverse the course of sympathetic ophthalmia in four patients. This subsidence of inflammation coincides with a decreased white blood cell count, after which all medications are discontinued or only topical steroids are needed to control the inflammation. The other three patients (17, 19, and 20) we treated with chlorambucil also showed this relationship.

Previous authors, using chlorambucil to treat uveitis patients unresponsive to systemic corticosteroids, did not always find this relationship between
chlorambucil is a secondary sexual teratogen,4 probably means that chlorambucil is also a mutagen. However, except for one 7-year-old girl who contracted acute leukaemia after receiving a total chlorambucil dose of 300 mg (15 mg/kg), acute leukaemia does not occur in patients treated with a total dose of less than 1 g.7

Table 2  Enucleation interval, disease severity, and final visual outcome*

<table>
<thead>
<tr>
<th>Patient no</th>
<th>Enucleation interval</th>
<th>Disease severity</th>
<th>Final visual acuity</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>4 days</td>
<td>Mild</td>
<td>20/100†</td>
</tr>
<tr>
<td>7</td>
<td>6 days</td>
<td>Moderate</td>
<td>20/20</td>
</tr>
<tr>
<td>15</td>
<td>8 days</td>
<td>Severe</td>
<td>20/40</td>
</tr>
<tr>
<td>18</td>
<td>4 days</td>
<td>Severe</td>
<td>20/20</td>
</tr>
<tr>
<td>20</td>
<td>11 days</td>
<td>Severe</td>
<td>20/20</td>
</tr>
</tbody>
</table>

Enucleation greater than 2 weeks

<table>
<thead>
<tr>
<th>Patient no</th>
<th>Enucleation interval</th>
<th>Disease severity</th>
<th>Final visual acuity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5 weeks</td>
<td>Mild</td>
<td>20/50</td>
</tr>
<tr>
<td>6</td>
<td>3 months</td>
<td>Moderate</td>
<td>CF‡</td>
</tr>
<tr>
<td>10</td>
<td>4 months</td>
<td>Moderate</td>
<td>HM†</td>
</tr>
</tbody>
</table>

* Patient 16 was not included owing to insufficient information.
†Patient 17 was not included because enucleation preceded the onset of sympathetic ophthalmia.
‡Patient 5 developed a cataract in this eye.
§CF=count fingers. HM=hand motion.

The anterior chamber inflammation diminishes concurrently with the white cell suppression as a result of drug therapy in patient 18. Occ indicates occasional cell; rare, rare cell. *80 mg alternated with 20 mg daily.

Infections, particularly herpes zoster, develop in patients who tend to be on prolonged chlorambucil therapy.18 None of our four patients had any of the complications mentioned, though evaluations of fertility were not determined.

We believe that chlorambucil should be administered in progressively larger dosages. By increasing the daily dose weekly, bone marrow depression is achieved earlier, thus eliminating the ocular inflammation sooner and allowing a more rapid withdrawal of systemic steroids. This is important if the patient is experiencing severe side effects from the steroids. Moreover, a rapid induction of bone marrow depression limits the total chlorambucil dose and, as discussed, the incidence of complications from the...
chlorambucil therapy. However, weekly platelet and white blood cell counts are imperative. Chlorambucil immunosuppressive therapy has caused irreversible bone marrow failure.19

Cyclosporin, another immunosuppressive agent, has been recently used to treat uveitis.20–23 In one study nine patients with refractory posterior uveitis were administered systemic cyclosporin. All patients had an improved visual acuity, a reduced steroid dose, and decreased inflammation. However, in seven patients cyclosporin-induced renal toxicity necessitated a reduction in the cyclosporin dose, which led to a relapse of the uveitis.24 Others have reported that the cyclosporin dose was tapered because of nephrotoxicity and that systemic corticosteroids had to be added to suppress the inflammation.25 This experience indicates that clinically cyclosporin suppresses but does not eradicate ocular inflammation. Thus patients with severe uveitis would need chronic cyclosporin therapy, which has been associated with renal toxicity26 and lymphoma.27 This is different from our experience with chlorambucil, in which only short-term therapy was required.

The authors were supported in part by training grant 7038 and core grant 1792 from the National Eye Institute, Bethesda, Md, and by an unrestricted research grant from Research to Prevent Blindness, Inc. New York.

References

15 Palmer RG, Dore CJ, Denman AM. Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative. Lancet 1984; i: 246–8.

Accepted for publication 19 January 1988.
Twenty cases of sympathetic ophthalmia.

T Jennings and H H Tessler

doi: 10.1136/bjo.73.2.140

Updated information and services can be found at:
http://bjo.bmj.com/content/73/2/140

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/